Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL-1001
- Development stage
- Discontinued
- Lead developer
- Stemline Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SL-1001 is a selective, oral small molecule inhibitor targeting RET (rearranged during transfection) kinase. It was rationally designed at the Cancer Research UK Manchester Institute and developed by Stemline Therapeutics. Its primary indication was for cancers driven by RET kinase alterations, with demonstrated preclinical anti-cancer activity in vitro and in vivo. SL-1001 was intended to offer high selectivity for RET to improve outcomes and reduce dose-limiting toxicities compared to less selective multikinase inhibitors. Clinical development has been discontinued[1][3][5][6][7].
- Other names
- SL 1001SL1001SL-1001
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on SL-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL-1001.